Long‐term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention‐deficit/hyperactivity disorder

AIMS: As an extension of a phase 2/3 study evaluating the efficacy and safety of lisdexamfetamine dimesylate (LDX) 30, 50, or 70 mg/d for 4 weeks in Japanese patients aged 6‐17 years with attention‐deficit/hyperactivity disorder (ADHD), this study evaluated its long‐term safety and efficacy. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Ichikawa, Hironobu, Miyajima, Tasuku, Yamashita, Yushiro, Fujiwara, Masakazu, Fukushi, Akimasa, Saito, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292222/
https://www.ncbi.nlm.nih.gov/pubmed/31814294
http://dx.doi.org/10.1002/npr2.12091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292222/
https://www.ncbi.nlm.nih.gov/pubmed/31814294
http://dx.doi.org/10.1002/npr2.12091

Ejemplares similares